X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Panacea Biotech with MYLAN INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs MYLAN (US) - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 PANACEA BIOTECH   MYLAN
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
MYLAN
Dec-14
PANACEA BIOTECH/
MYLAN
5-Yr Chart
Click to enlarge
High Rs1493,830-   
Low Rs822,699-   
Sales per share (Unadj.) Rs84.11,311.3-  
Earnings per share (Unadj.) Rs-18.3158.0-  
Cash flow per share (Unadj.) Rs-6.7254.3-  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs83.7651.9-  
Shares outstanding (eoy) m61.25378.37-   
Bonus/Rights/Conversions -OI-  
Price / Sales ratio x1.42.5 55.1%   
Avg P/E ratio x-6.320.7 -30.5%  
P/CF ratio (eoy) x-17.212.8 -134.3%  
Price / Book Value ratio x1.45.0 27.5%  
Dividend payout %00-   
Avg Mkt Cap Rs m7,0741,235,346 0.6%   
No. of employees `0002.825.0 11.0%   
Total wages/salary Rs m1,4490-   
Avg. sales/employee Rs Th1,874.119,846.6 9.4%   
Avg. wages/employee Rs Th527.00-   
Avg. net profit/employee Rs Th-407.72,390.8 -17.1%   
INCOME DATA
Net Sales Rs m5,154496,164 1.0%  
Other income Rs m100-2,892 -3.5%   
Total revenues Rs m5,254493,272 1.1%   
Gross profit Rs m-766123,398 -0.6%  
Depreciation Rs m71136,441 2.0%   
Interest Rs m1,50321,402 7.0%   
Profit before tax Rs m-2,88162,663 -4.6%   
Minority Interest Rs m11-257 -4.2%   
Prior Period Items Rs m-60-   
Extraordinary Inc (Exp) Rs m1,7710-   
Tax Rs m172,635 0.6%   
Profit after tax Rs m-1,12159,771 -1.9%  
Gross profit margin %-14.924.9 -59.8%  
Effective tax rate %-0.64.2 -13.9%   
Net profit margin %-21.812.0 -180.6%  
BALANCE SHEET DATA
Current assets Rs m3,810436,194 0.9%   
Current liabilities Rs m8,365341,017 2.5%   
Net working cap to sales %-88.419.2 -460.8%  
Current ratio x0.51.3 35.6%  
Inventory Days Days15678 199.4%  
Debtors Days Days67107 62.7%  
Net fixed assets Rs m14,480114,786 12.6%   
Share capital Rs m6117,546 0.3%   
"Free" reserves Rs m9030-   
Net worth Rs m5,127246,643 2.1%   
Long term debt Rs m5,832368,460 1.6%   
Total assets Rs m19,433993,454 2.0%  
Interest coverage x-0.93.9 -23.3%   
Debt to equity ratio x1.11.5 76.1%  
Sales to assets ratio x0.30.5 53.1%   
Return on assets %2.08.2 24.0%  
Return on equity %-21.924.2 -90.2%  
Return on capital %3.613.6 26.7%  
Exports to sales %24.50-   
Imports to sales %10.20-   
Net fx Rs m5970-   
CASH FLOW
From Operations Rs m59965,221 0.9%  
From Investments Rs m-438-51,435 0.9%  
From Financial Activity Rs m-303-17,186 1.8%  
Net Cashflow Rs m-141-3,400 4.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 64.27 Rs / USD

Compare PANACEA BIOTECH With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare PANACEA BIOTECH With: IPCA LABS  DIVIS LABORATORIES  ALEMBIC LTD  GLENMARK PHARMA  NATCO PHARMA  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Related Views On News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Feb 16, 2018 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH - ELDER PHARMA COMPARISON

COMPARE PANACEA BIOTECH WITH

MARKET STATS